Market News

Amgen (AMGN)

Amgen announced that the Phase 3 PRIME 203 trial evaluating Vectibix (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.
Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging progression-free survival (PFS) in the first-line treatment of patients with KRAS wild-type mCRC.

Nov 5 · 3:29:00 PM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Gilead Sciences (GILD)

Gilead Sciences today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.
These new data show that the majority of patients who received Viread for up to 144 weeks experienced sustained suppression of HBV DNA levels in the blood to below 400 copies/mL (87 percent in Study 102 and 71 percent in Study 103). Additionally, cumulatively over 144 weeks, 8 percent of all patients in Study 103 (HBeAg-positive) experienced “s” antigen (HBsAg) loss, which can contribute to resolution of chronic hepatitis B infection. Notably, no mutations associated with resistance to Viread developed in any patients up to 144 weeks of treatment.

Nov 5 · 1:02:00 PM · Source: Business Wire
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

IMS Health (RX)

IMS Health announced Thursday it has entered into a definitive agreement to be acquired by investment funds managed by TPG Capital and the CPP Investment Board in a transaction with a total value of $5.2 billion, including the assumption of debt.

Nov 5 · 11:54:00 AM · Source: Company News
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Amgen (AMGN)

Amgen, Inc. and AmerisourceBergen Corp. were sued on Friday by 14 U.S. states and the District of Columbia over an alleged kickback scheme designed to boost sales of Amgen's anemia drug, Aranesp.
New York Attorney General Andrew Cuomo announced the lawsuit, which was filed in federal court in Boston. It joins a related whistleblower lawsuit filed in the same court in 2006 and is one of many lawsuits accusing drugmakers of illegally marketing their products.

Nov 3 · 1:30:00 PM · Source: Reuters · Related: AmerisourceBergen
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Abbott Labs (ABT)

Abbott announced that it has completed its acquisition of Evalve, Inc., the global leader in the development of devices for minimally invasive repair of mitral valves.
The acquisition provides Abbott with a leading presence in the growing area of non-surgical treatment for structural heart disease. Evalve's minimally invasive catheter-based MitraClip® system is the first commercially available treatment option approved in Europe for non-surgical mitral valve repair for patients suffering from the effects of mitral regurgitation, a condition that prevents the heart's mitral valve from closing completely.

Nov 3 · 11:43:00 AM · Source: Reuters
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto

Johnson & Johnson (JNJ)

Johnson & Johnson said Tuesday it will cut up to 7% of its global workforce as part of an ongoing cost-cutting plan that the company says will save between $1.4 and $1.7 billion by 2011. The consumer health product maker has about 117,000 employees spread across more than 250 companies.

Nov 3 · 9:59:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Humana (HUM)

Humana said Monday that it had third-quarter net income of $301.5 million, or $1.78 per share, compared with $183 million, or $1.09 per share, a year earlier. Revenue rose 8 percent to $7.72 billion.
Analysts had expected $7.82 billion in revenue.

Nov 2 · 1:01:00 PM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Sanofi-Aventis Sa (SNY)

Sanofi-Aventis Friday said its third-quarter net profit rose 6.8% to EUR1.42 billion compared with EUR1.33 billion a year ago. Sales rose 8% to EUR7.4 billion from EUR6.85 billion a year ago.
Sales were above analysts' estimates of EUR7.37 billion

Oct 30 · 8:58:00 AM · Source: Company News Release
Track · email · face · Twitter · digg · COMMENTS
by Larry Etter

Previous · Next